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Hepatitis C virus (HCV) interacts with cellular components andmodulates their activities for its own benefit. These interactions
have been postulated as a target for antiviral treatment, and some candidate molecules are currently in clinical trials. The multi-
functional cellular kinase Akt/protein kinase B (PKB) must be activated to increase the efficacy of HCV entry but is rapidly inac-
tivated as the viral replication cycle progresses. Viral components have been postulated to be responsible for Akt/PKB inactiva-
tion, but the underlying mechanism remained elusive. In this study, we show that HCV polymerase NS5B interacts with Akt/
PKB. In the presence of transiently expressed NS5B or in replicon- or virus-infected cells, NS5B changes the cellular localization
of Akt/PKB from the cytoplasm to the perinuclear region. Sequestration of Akt/PKB by NS5B could explain its exclusion from its
participation in early Akt/PKB inactivation. The NS5B-Akt/PKB interaction represents a new regulatory step in the HCV infec-
tion cycle, opening possibilities for new therapeutic options.
Hepatitis C virus (HCV) is a positive-strand RNA virus[RNA()] responsible for chronic infections in almost
200 million people worldwide. HCV-positive patients are at
high risk of developing cirrhosis and hepatocellular carcinoma
(1). As an obligate parasite, HCV usurps cellular functions and
pathways to complete its replication cycle, and some of these
routes are related to cell cycle control (2). The Akt/protein
kinase B (PKB) family of serine/threonine protein kinases are
involved in several signaling pathways that can impact the out-
come of viral infections. Akt/PKB resides in the cytosol in an
inactive conformation. Initial stimulation of the cell causes
activation of a cell surface receptor and subsequently phos-
phorylation of phosphatidylinositol 3-kinase (PI3K). Activated
PI3K is responsible of the formation of phosphatidylinosi-
tol(3,4,5)-trisphosphate second messenger. Akt interacts with
these phosphoinositides and is recruited to the membrane,
where it can be fully activated by PDK1 and other kinases. The
Akt/PKB pathway is involved in processes as disparate as nu-
trient metabolism, regulation of protein synthesis, autophagy,
and the balance of apoptosis versus cell survival and prolifera-
tion, the latter being critical for the outcome of viral infections
(3–6). Akt/PKB can influence the virus-host interaction by sev-
eral mechanisms. The translational repressors 4E-BPs are eu-
karyotic translation initiation factor 4E (eIF4E)-binding pro-
teins that prevent cap-dependent translation of cellular
mRNAs. Akt/PKB is needed for the inactivation of 4E-BPs,
which occurs through a phosphorylation reaction that requires
FRAP/mammalian target of rapamycin (mTOR) and results in
activation of cellular translation (7). Akt/PKB is the down-
stream target of the lipid kinase PI3K, and both are involved in
cell proliferation and apoptosis. In infections of neuronal cells
by dengue virus serotype 2 (dengue-2) and Japanese encepha-
litis virus, PI3K played an antiapoptotic role, and the blocking
of PI3K activation enhanced virus-induced cytopathology with
no effect on virus production (8). These multiple effects of
Akt/PKB can modulate cap- versus internal ribosome entry site
(IRES)-dependent translation as well as infected-cell survival,
which may facilitate virus persistence. Thus, not surprisingly,
several viral proteins can modulate PI3K/Akt-dependent sig-
naling pathways (9–12).
We are interested in the viral and cellular factors that may
modify the replicative fitness of HCV, thereby permitting HCV
persistence, a hallmark of the infection by this virus in vivo. No
unified picture has been derived from previous descriptions of
the interaction of HCV and Akt/PKB-dependent pathways. An
early and transient activation of the PI3K/Akt/mTOR pathway
by the HCV E2 glycoprotein resulted in enhancement of HCV
entry into the cell (13). This activation took place 15 min
postinfection (p.i.), but at 24 h p.i. the levels of activated Akt/
PKB were no longer significant. Since inactivation of PI3K/Akt
required infectious virus, the involvement of HCV gene prod-
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ucts in the inactivation was postulated (13). Chemical Akt/PKB
inhibition with Akt-II and Akt-V inhibitors as well as genetic
inhibition with small interfering RNAs (siRNAs) resulted in a
reduction of infectivity (13). Furthermore, such inactivation
and the downstream inhibition of the PI3/Akt/mTOR pathway
resulted in HCV-induced autophagy (14), which may contrib-
ute to membrane rearrangements to accommodate replication
complexes (15, 16). Similar results have been recently observed
using mTOR inhibitors (17). How the transition of Akt/PKB
from an early-activated plasma membrane-bound form to a
cytoplasm location takes place is not known.
In the present report, we describe a new functional activity
of the HCV polymerase NS5B that consists of interaction with
Akt/PKB, resulting in translocation of this key kinase from the
cytoplasm to the perinuclear region, where the two proteins
colocalize. This Akt/PKB relocalization may be an additional
mechanism of temporal modulation of its cytoplasmic activity
and recruitment to assist in replicative functions. Akt/PKB re-
localization by virtue of its interaction with NS5B could have
additional consequences for HCV, from limitation of cell entry
to phosphorylation of viral components of the replicative com-
plexes. Several Akt/PKB inhibitors are currently in clinical tri-
als, and this signaling pathway could be also targeted for treat-
ment of HCV infection.
MATERIALS AND METHODS
Reagents, expression plasmids, and inhibitors. Plasmid pDest14-
NS5B21-FP encoding HCV NS5B fused to citrine and plasmid pRSET-
citrine, which encodes citrine, as well as vectors to overexpress Akt/PKB
tagged with the hemagglutinin (HA) epitope (pcFEL) and NS5B tagged
with citrine (pcDNA-Dest40-NS5B-citrine), have been described previ-
ously (18, 19). Recombinant Akt/PKB was purchased from Biaffin (Biaffin
GmbH & Co), Akt/PKB inhibitor MK2206 from Selleckchem, Lipo-
fectamine 2000 from Invitrogen, and G418 from Lonza. Huh7.5 cells and
HCV subgenomic replicon pI389/NS3-3=/LucUbiNeo-ET were kindly
provided by R. Bartenschlager (University of Heidelberg, Heidelberg,
Germany) (20). The following antibodies were used: anti-HA (BAbCo), anti-
green fluorescent protein (anti-GFP; Covance), anti-NS5B (ab35586; Ab-
cam), anti-Akt and anti-pAkts473 (Cell Signaling Technology), and anti-
tubulin (Santa Cruz Technology). Alexa Fluor 488- and 546-conjugated
antibodies (Invitrogen) were used as fluorescent secondary antibodies.
HCV NS5B21-FP and GFP purification. Point mutants in
NS5B21 fused to citrine were generated by site-directed mutagenesis
according to the manufacturer’s instructions (QuikChange site-directed
mutagenesis; Agilent Technologies). Synthetic oligonucleotides used for
point mutant generation are described in Table S1 in the supplemental
material, and chromatograms from sequencing results are shown in Fig.
S1B in the supplemental material. Wild-type NS5B21 and mutants of
NS5B21 fused to citrine as well as recombinant citrine were overex-
pressed and purified as described previously (19, 21). Briefly, Escherichia
coli Rosetta cells (Novagen) were transformed with construct pDest14-
NS5B21-FP, encoding the NS5B-FP fusion protein, or with pRSET-cit-
rine, encoding recombinant citrine protein. Cells expressing the protein
of interest were collected, and the protein was purified by affinity chro-
matography. SDS-PAGE and Coomassie blue staining were performed to
evaluate the purification steps. Fractions showing the purest and most
concentrated protein were pooled, dialyzed against dialysis buffer (20 mM
Tris-HCl [pH 7.0], 1 M NaCl, 10% glycerol), and stored at 4°C. SDS-
PAGE and Coomassie blue staining were used to monitor all purification
steps. Final purified proteins were quantified by densitometry. Only pro-
teins with at least 95% purity as judged by SDS-PAGE and Coomassie blue
staining were used for further experiments.
In vitro kinase assay. HCV NS5B-FP, NS5B-FP point mutants, or
citrine protein (1.6g) was incubated in hot kinase buffer (20 mM HEPES
[pH 7.4], 10 mM MgCl2, 10 mM MnCl2, 1 Ci of [-
32P]ATP, 1 mM
dithiothreitol [DTT]) in the presence of 0.5 g of recombinant Akt/PKB
(Biaffin GmbH & Co). The products were separated on an SDS-PAGE gel.
After electrophoresis, the gel was dried and radiolabeled products were
detected by autoradiography. Alternatively, dried gels were exposed to
phosphorimager screens and scanned with Typhoon9600 (Molecular Dy-
namics).
In vitro RNA-dependent RNA polymerase (RdRP) replication as-
says. RNA polymerase assays were performed using the symmetric sub-
strate LE-19 (sequence 5= UGUUAUAAUAAUUGUAUAC 3=), which is
capable of de novo initiation (DN), primer extension (PE), and template
switching (TS) as previously described (19). Except when indicated oth-
erwise, 200 nM NS5B was preincubated for 30 min in a reaction mixture
containing 20 mM MOPS (morpholinepropanesulfonic acid) (pH 7.3)
and 5 mM MnCl2, in the presence or absence of Akt (0.5 g of recombi-
nant Akt/PKB [Biaffin GmbH & Co]), and supplemented or not with ATP
(500 M), as indicated in the figure legend. Reactions were started by
adding 500 M GTP, 100 M ATP and UTP, and 1 Ci [-32P]CTP
(3,000 Ci/mmol; PerkinElmer Life Sciences). Reactions were stopped with
EDTA/formamide loading buffer at different time points as indicated.
Products were separated using denaturing polyacrylamide (23% phos-
phonoacetic acid [PAA], 7 M urea) gel electrophoresis. Gels were exposed
to phosphorimager screens and scanned with Typhoon (Molecular Dy-
namics). Quantification was obtained by running samples on parallel gels
and determining band volumes using ImageQuant software (GE Health-
care).
In vitro transcription, electroporation, and colony formation. After
digestion with ScaI, replicon DNA was extracted with phenol-chloroform.
In vitro transcription was performed with 1 g of digested DNA and the
Megascript T7 kit (Ambion) according to the manufacturer’s instruc-
tions. The RNA obtained was purified with the MegaClear kit (Ambion),
quantified, and stored at 80°C until use. Huh7.5 cells were electropo-
rated with transcribed RNA from the replicon using the Electrobuffer kit
(Cell projects, Iberlabo, Madrid, Spain), in accordance with the manufac-
turer’s instructions. Briefly, exponentially growing cells were harvested
and washed with electroporation medium. Four micrograms of replicon
RNA and 6 g of carrier Huh7.5 RNA were mixed with the electropora-
tion medium and added to 4  106 cells. The cell suspension was pulsed
once with Gene Pulser II (settings, 975 F and 270 V; Bio-Rad). After
electroporation, 2  106 cells (and 1/10 and 1/20 dilutions) were seeded
on petri dishes in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich Química, Madrid, Spain) with 10% fetal bovine serum (HyClone,
Fisher Scientific, Madrid, Spain), supplemented with 1 M HEPES
(Sigma), 1% glutamine, nonessential amino acids, antibiotics (penicillin,
streptomycin), and sodium pyruvate. Cells were kept at 5% CO2 and
37°C. Twenty-four hours later, the DMEM culture medium was replaced
with fresh medium containing G418 (Labclinics, Barcelona, Spain), after
which the medium was refreshed twice per week for 2 weeks.
Cell culture virus infection. The origin of the Huh-7.5 cell line, pro-
cedures for cell growth in DMEM, the virus used in the experiments res-
cued from plasmid Jc1FLAG2(p7-nsGluc2A) (a chimera of J6 and JFH-1
from genotype 2a), and the procedures used to prepare the initial virus
stock HCVp0, to titrate viral infectious particles, and to quantify viral
RNA have been previously described (23, 24). To perform infections for
immunofluorescence and RNA quantification assays, 1  105 Huh7.5
cells were infected with HCVp0 at a multiplicity of infection (MOI) of 0.5
50% tissue culture infective dose (TCID50)/cell. After 5 h of virus adsorp-
tion, supernatants were replaced with fresh medium with or without the
inhibitor MK-2206. The infected cells were further incubated at 37°C for
2 h and 43 h. To perform infections with HCVp0 for coimmunoprecipi-
tation assays, 4 106 Huh7.5 cells were infected with HCVp0 at an MOI
of 0.5 TCID50/cell. After 5 h of virus adsorption, supernatants were re-
placed with 10 ml of fresh medium. The infected cells were further incu-
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bated at 37°C for 72 h. The absence of contamination was checked by
maintaining and titrating mock-infected cells and their supernatants in
parallel with the infected cultures. No infectivity in the mock-infected
cultures was detected in any of the experiments.
Coimmunoprecipitation. Huh7.5 cells from either transfection or in-
fection experiments were collected 48 h posttransfection or postinfection
in HNTG lysis buffer (25 mM HEPES [pH 7.5], 0.3 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic
acid, 20 mM B-glycerophosphate) containing protease and phosphatase
inhibitors (2 g/ml leupeptin, 2 g/ml aprotinin, 1 mM phenylmethyl-
sulfonyl fluoride [PMSF], and 0.1 mM Na3VO4). Cell lysates were centri-
fuged at 12,000 g for 1 min at 4°C. Supernatants were recovered, mixed
with 1 g of primary antibody, and incubated for 2 h at 4°C. After this,
reaction mixtures were incubated for 3 h with protein G (Gamma Bind
Sepharose; Amersham) and washed once in HNTG lysis buffer. Protein G
agarose-bound immune complexes were collected by centrifugation at
12,000 g for 1 min and washed once with lysis buffer, and proteins were
detected by Western blotting.
Western blot analysis. Protein quantification was performed using
the bicinchoninic (BCA) protein assay kit (Pierce, Madrid, Spain) accord-
ing to the manufacturer’s instructions. Samples were separated on 10%
SDS-PAGE gels and transferred onto Immobilon-P membranes (Millipore).
Membranes were probed with primary antibodies as indicated in the corre-
sponding figures. The proteins were visualized using suitable horseradish per-
oxidase (HRP)-conjugated secondary antibodies (Santa Cruz Biotechnol-
ogy). Antibody detection was achieved by enhanced chemiluminescence
(Amersham, GE Health Care) in an LAS-3000 system (FujiFilm, Japan). Tu-
bulin was used as a loading control.
FIG 1 (A) Structure of NS5B. HCV replicase NS5B from strain HC-J4 genotype 1b (47) is depicted in ribbons showing the fingers (blue), palm (red), and thumb
(green) domains. Sites that can potentially be phosphorylated by Akt/PKB are depicted as yellow spheres. (B) HCV NS5B surface showing the Akt/PKB
phosphorylation sites (yellow) as well as loops 1 and 2. Color codes are as described for panel A. Ser453, Thr53, Thr520, Ser84, Ser506, Ser46, and Ser513
displayed percentages of relative surface accessibility of 14.5%, 21.7%, 24.5%, 36.2%, 39.7%, 43.5%, and 78.9%, respectively. (C) SDS-PAGE (10%) analysis of
proteins NS5B, Akt/PKB, NS5B-FP, and citrine. Molar mass markers are depicted on the right. (D) In vitro kinase assay. Reaction products were resolved in a 10%
SDS-PAGE gel. Concentration of inhibitor MK-2206 is in nanomolar values. MW, molecular weight (in thousands). (E) In vitro kinase assay products resolved
in a 12% SDS-PAGE gel, with the assay performed as described for panel D but using recombinant citrine as the substrate for Akt/PKB. In panels D and E, the
presence or absence of the different components of the reactions is shown below the gel. (F) In vitro kinase assay (as described for panel D) using the indicated
NS5B-FP point mutants as the substrate. Positions of protein markers are indicated on the left (panels D to F).
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Real-time RT-PCR for RNA quantification. Akt/PKB mRNA was
quantified by quantitative real-time PCR (qRT-PCR) using an ABIPrism
7500 FAST Sequence detection system (Applied Biosystems). cDNA was
amplified using the SYBR1 Green PCR master mix (Applied Biosystems)
in the presence of specific oligonucleotides Akt_sense (5=-ACATCTGTC
CTGGCACAC-3=; sense orientation) and Akt_antisense (5=-GCCAGTG
CTTGTTGCTTG-3=; antisense orientation). The conditions for RT-PCR
amplification and RNA quantification were as previously described (25).
Primers for qPCR were designed using Primer Express software, which
was provided with the 7000 Sequence detection system (Applied Biosys-
tems). Oligonucleotides were purchased from Thermo Scientific (Ma-
drid, Spain). HCV RNA real-time quantitative RT-PCR was carried out
using the Light Cycler RNA Master SYBR green I kit (Roche) according to
the manufacturer’s instructions. The 5=-untranslated (5=-UTR) noncod-
ing region of the HCV genome was amplified using oligonucleotides
HCV-5UTR-F2 (5=-TGAGGAACTACTGTCTTCACGCAGAAAG; sense
orientation), and HCV-5UTR-R2 (5=-TGCTCATGGTGCACGGTCTAC
GAG; antisense orientation). Quantification was performed relative to a
standard curve obtained with known amounts of HCV RNA, synthesized
by in vitro transcription of plasmid GNN DNA.
FIG 2 Effects of Akt/PKB inhibition by MK-2206 on HCVp0 replication. (A) Viral titer in the supernatant of infected cultures was sampled at 7 h or 48 h
postinfection (p.i.) in the presence of the indicated MK-2206 concentrations. (B) Intracellular HCV RNA at 7 h or 48 h p.i. in the presence of indicated MK-2206
concentrations. (C) Fold changes of viral titer in the supernatant from 7 h to 48 h p.i. (D) Fold changes of intracellular HCV RNA titer from 7 h to 48 h p.i. (E)
Viability of Lunet cells in the presence (open circles) or absence (filled squares) of MK-2206 (10 M). Time zero represents the time at which MK-2206 was
added. Values are the averages from three determinations. Standard deviation values are smaller than the graph symbols and therefore not visible. P values
obtained with Student’s t tests are shown.
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The specificity of the qRT-PCRs was monitored by determining the
denaturation curves of the amplified DNAs. Negative controls (without
template RNA and/or with RNA from mock-infected cells) were run in
parallel with each amplification reaction to ascertain the absence of con-
tamination with undesired templates.
Immunofluorescence assays. The immunocytochemistry protocol
was the same for transfected and HCVp0-infected Huh7.5 cells.
Briefly, at the desired time points, cells situated on coverslips that were
previously treated with poly-L-lysine (Sigma) were fixed in 4% para-
formaldehyde for 10 min, permeabilized with 0.2% Triton X-100 for
10 min, washed in phosphate-buffered saline (PBS), and blocked with
5% bovine serum albumin (BSA; Sigma). Samples were incubated
overnight in 0.5% BSA with primary antibodies (1:1,000) in various
combinations, as indicated in the corresponding figures. After washing
with PBS, samples were incubated with fluorescent secondary antibod-
ies. Nuclei were visualized with 4=,6-diamidino-2-phenylindole
(DAPI; Invitrogen). Images of the samples were taken using a Zeiss
LSM-710 confocal microscope.
Statistical analyses. Statistical comparisons among groups were per-
formed with Student’s t tests. Significant differences (P 0.05) between
data sets are indicated. Those with P values of 0.01 were considered
highly significant.
RESULTS
In vitro phosphorylation of NS5B by Akt/PKB. Akt/PKB phos-
phorylates Ser and Thr residues within the minimal consensus
sequence ArgXArgXX(Ser/Thr)h, where X is any amino acid and h
is a bulky hydrophobic amino acid (22, 26). We scanned the HCV
polyprotein amino acid sequence using Scansite software (27) and
observed an accumulation of exposed putative Akt-driven phos-
phorylation sites in NS5B (Fig. 1A and B). Relative residue surface
accessibility was investigated using the NetSirfP program (28) and
the “accessible surface area and accessibility calculation for pro-
tein” tool (Center for Informational Biology, Ochanomizu Uni-
versity; http://cib.cf.ocha.ac.jp/bitool/ASA/). Nine NS5B residues
were recognized as possible targets of Akt/PKB (Fig. 1A). Amino
FIG 3 RNA synthesis in the presence of active Akt. (A) RNA-dependent
RNA polymerase activity (in arbitrary units) using LE19 RNA as a template
under different conditions. HCV NS5B was incubated in MOPS (20 mM)
buffer and MnCl2 (5 mM) (black), supplemented with Akt (gray) or Akt
plus ATP (white) for 30 min at room temperature. After incubation, the
reaction was started by adding nucleotides, LE19 RNA, and alpha-32P-
CTP. Aliquots were stopped at 15 min and 30 min and resolved in dena-
turing polyacrylamide gels. De novo (DN), primer extension (PE), and
template switching (TS) products were quantified. Values are the averages
and corresponding standard errors of the means (SEM) from at least four
independent experiments. *, P 0.05; **, P 0.01. (B) Representative gel
image of the values given in panel A. The positions of DN, PE, and TS
products are indicated. Preincubation conditions as well as the times at
which the RNA synthesis reaction was stopped are indicated below the
image. (C) In vitro phosphorylation of NS5B by recombinant Akt under the
reaction conditions used for panels A and B. NS5B-FP was used instead of
NS5B to differentiate between HCV polymerase and Akt, as in Fig. 1. Buffer
conditions were the same as those used for RNA synthesis. Positions of
protein markers are indicated on the left.
FIG 4 Coimmunoprecipitation of Akt/PKB and NS5B. (A) SDS-PAGE
(10%) analysis of immunoprecipitated protein from lysates of Huh7.5 cells
transiently transfected with pcDNA3 empty vector (control, lane 1), HA-
tagged Akt/PKB (pcFEL, lane 2), NS5B-FP (pcDNA-Dest40-NS5B-FP, lane
3), and Akt/PKB plus NS5B-FP (lane 4). Cell protein extracts were immu-
noprecipitated with anti-GFP (lanes 1, 3, and 4) or anti-HA (lane 2) anti-
bodies and then immunoblotted using an anti-Akt antibody (upper panel).
The asterisk indicates the product of immunoprecipitation. Total cell ly-
sates (50 g) used in the coimmunoprecipitation experiment were frac-
tionated on SDS-PAGE and immunostained using anti-Akt, anti-NS5B,
and antitubulin antibodies (Akt/PKB, NS5B, and tubulin panels). (B) Co-
immunoprecipitation experiment performed using extracts from HCVp0-
infected Huh7.5 cells. Cell extracts were immunoprecipitated with an anti-
NS5B antibody and then immunoblotted using an anti-Akt antibody
(upper panel). The asterisk indicates the product of immunoprecipitation.
Total cell lysates (50 g) used in the coimmunoprecipitation experiment
were fractionated and immunoblotted with anti-NS5B and anti-Akt anti-
bodies (NS5B and Akt/PKB panels). Results show representative blots from
three independent experiments with nearly identical results. Sizes of mo-
lecular markers are indicated on the left in kilodaltons.
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acids Thr227 and Thr389 were buried, with low relative surface
accessibilities of 9% and 10%, respectively, while residues Ser453,
Thr53, Thr520, Ser84, Ser506, Ser46, and Ser513 displayed relative
surface accessibilities ranging from 14% to 79% (Fig. 1A and B).
Furthermore, the exposed residues are located in flexible sub-
domains that may alter their exposure during the catalytic cycle
(29). Therefore, the majority of the putative Akt/PKB phosphor-
ylation sites in NS5B are sufficiently surface exposed to be a sub-
strate for this kinase.
When investigating HCV NS5B in vitro phosphorylation by
Akt/PKB, it is important to distinguish between phosphorylation
of NS5B and Akt/PKB self-phosphorylation because the two pro-
teins have a similar molar mass of about 65 kDa (Fig. 1C). For this
reason, an in vitro phosphorylation assay was performed using a
recombinant NS5B fused to the GFP derivative citrine (NS5B-FP)
that renders a fusion protein of 90 kDa (19). The assay revealed
phosphorylation of both proteins, but phosphorylation of
NS5B-FP was dependent on the presence of Akt/PKB (Fig. 1D).
Akt/PKB inhibitor MK-2206 inhibited NS5B phosphorylation in a
concentration-dependent manner (Fig. 1D). No phosphorylation
of recombinant citrine (27 kDa) (Fig. 1C) by Akt/PKB was ob-
served (Fig. 1E). We concluded that Akt/PKB phosphorylates
HCV NS5B in vitro.
Ser or Thr residues at positions 53, 84, 227, and 543 were
totally conserved among genotypes 1 to 7 (see Fig. S1A in the
supplemental material). Thr at position 389 was almost totally
conserved for genotypes 1, 2, 3, and 7, and Ser at position 506
was conserved only for genotype 1 (see Fig. S1A in the supple-
mental material). These six positions with different levels of
conservation among genotypes were mutated to Ala in the con-
text of the NS5B-FP fusion protein (see Fig. S1B in the supple-
mental material). We also constructed and purified the double
mutant T53A/S506A, because both positions are involved in
NS5B-NS5B interactions and modifications in their side chains
might affect protein-protein contacts (29). The resulting pro-
teins were overexpressed, and purified proteins were subjected
to the in vitro kinase assay as described above. None of these
mutants lost their ability to be phosphorylated by Akt (Fig. 1F).
This result indicates that Akt phosphorylates more than one
residue or that Akt phosphorylates NS5B in noncanonical or
nonconserved sequences.
Effect of Akt/PKB inhibition on HCV replication. To con-
firm the implication of Akt/PKB in the replicative cycle of
HCV, experiments were performed using our in vivo experi-
mental system (23). Previous studies have established that
some Akt/PKB inhibitors such as Akt-II and Akt-V, as well as
siRNAs targeting Akt, impair HCV replication (13, 14). MK-
2206 is a highly selective inhibitor of Akt currently in clinical
trials (https://clinicaltrials.gov). MK-2206 has a 50% inhibi-
tory concentration (IC50) in the low nanomolar range, and it
does not show inhibitory activities against 250 other protein
kinases. For these reasons and because this inhibitor was not
used in HCV propagation experiments before, MK-2206 was
tested in HCVp0-infected Huh7.5 cells, as described in Mate-
rials and Methods. Viral RNA from MK-2206-treated and un-
treated cells was quantified at different postinfection time
points (Fig. 2). Viral infectivity in the cell culture supernatant
showed little variation at 7 h p.i. However, it decreased in an
inhibitor dose-dependent manner at 48 h p.i. (Fig. 2A). Intra-
cellular viral RNA slightly increased with elevated inhibitor
concentrations at 7 h p.i., whereas it remained invariant at 48 h
p.i. (Fig. 2B). We compared the values obtained at 48 h and 7 h
as a measure of how the infection was being developed in both
treated and untreated cells for each experimental condition.
Both HCV infectivity and HCV RNA ratios showed statistically
significant decreases in an inhibitor dose-dependent manner
(Fig. 2C and D). Cellular viability was not significantly altered
(Fig. 2E).
Effect of NS5B phosphorylation on polymerase activity.
NS5B is phosphorylated by Akt (Fig. 1C and D), and Akt inhi-
bition induced a decrease in HCV infectivity (Fig. 2). To ana-
lyze the effect of NS5B phosphorylation on RNA-dependent
RNA polymerase activity, HCV NS5B was preincubated at
room temperature with recombinant Akt or with Akt in com-
bination with ATP as described in Materials and Methods. Af-
ter this, the RNA synthesis reaction was started by adding nu-
cleotides and radioisotope and stopped after 15 or 30 min (Fig.
3A and B). Akt is able to phosphorylate NS5B under these
FIG 5 Effects of NS5B on Akt/PKB mRNA and protein levels. (A) Akt/PKB protein detection. Huh7.5 cells expressing Akt/PKB and/or NS5B were
collected and lysed, and 50 g of total cell lysates was fractionated and blotted against Ser473-phosphorylated Akt/PKB (upper part), Akt/PKB (middle
part), or NS5B (lower part). Lane 5 was loaded with activated Akt/PKB (from insulin-treated cells) as a positive control of S473P-Akt antibody. (B)
Akt/PKB mRNA quantification. Real-time RT-PCR results obtained with Huh7.5 cells transiently transfected with Akt/PKB, NS5B, or Huh7.5 cells
carrying the pI389/NS3-3=/LucUbiNeo-ET HCV subgenomic replicon (R). Measurements from cells without Akt/PKB transfection correspond to
endogenous Akt/PKB mRNA. Average values and standard deviations for two independent experiments performed in triplicate are shown. Procedures are
described in Materials and Methods.
Subcellular Relocalization of Akt/PKB by HCV NS5B
June 2016 Volume 60 Number 6 aac.asm.org 3545Antimicrobial Agents and Chemotherapy
 o
n







conditions (Fig. 3C). The presence of Akt and especially Akt
plus ATP inhibited the RNA polymerase activity of NS5B. This
effect was strongest upon 30 min of reaction. All reactions
carried out by HCV NS5B, that is, de novo initiation (DN),
primer extension (PE), and template switching (TS), were af-
fected (Fig. 3A and B). Therefore, the presence of Akt in the
reaction mixture, and especially NS5B phosphorylation by Akt,
decreased polymerase activity.
Interaction of Akt/PKBwith NS5B. Next, we tested a possible
in vivo interaction between NS5B and Akt/PKB. A lysate from
cells transiently cotransfected with plasmids encoding Akt/PKB
(tagged with an HA epitope in the plasmid pcFEL) and NS5B-FP
(pcDNA-Dest40-NS5B-citrine) was immunoprecipitated with
anti-GFP (to precipitate NS5B-FP) and blotted with anti-HA (to
visualize Akt/PKB). A band of a molar mass compatible with Akt/
PKB was obtained (Fig. 4A). To confirm this result, cell lysate was
immunoprecipitated with anti-HA and blotted with anti-GFP. A
band of a molar mass compatible with NS5B-FP was obtained (see
Fig. S2 in the supplemental material). To examine the interaction
in the context of the HCV polyprotein, coimmunoprecipitation
experiments were additionally performed using HCV-infected
Huh7.5 cells as described in Materials and Methods. In extracts of
HCVp0-infected cells, a band with the expected size of the endog-
enous Akt/PKB was detected in the fraction immunoprecipitated
with anti-NS5B (Fig. 4B). Therefore, NS5B also interacts with Akt/
PKB in infected cells.
Next, we examined if the interaction of NS5B with Akt/PKB
induced changes in cellular Akt/PKB at the level of mRNA or
protein and also in the phosphorylation status of Akt/PKB. Trans-
fection of Huh7.5 cells with a plasmid encoding NS5B-FP
(pcDNA-Dest40-NS5B-citrine) did not change Akt/PKB protein
levels, Akt/PKB activation, or Akt/PKB mRNA levels (Fig. 5).
Thus, NS5B interacts with Akt/PKB without affecting Akt/PKB
mRNA or protein.
Intracellular localization of Akt/PKB and NS5B. To identify
the intracellular site of the interaction between Akt/PKB and HCV
NS5B, Huh7.5 cells were transfected with plasmids encoding Akt/
PKB (pcFEL) and NS5B-FP (pcDNA-Dest40-NS5B-citrine), and the
expressed proteins were localized by confocal microscopy. In resting,
unstimulated Huh7.5 cells, Akt/PKB was uniformly distributed in
the cytoplasm, as previously described (30), and the NS5B distri-
bution was perinuclear, also as expected from previous results
(31) (Fig. 6A, Akt-HA and NS5B-FP panels). In contrast, in
Huh7.5 cells cotransfected with plasmids expressing the two pro-
teins, the subcellular localization of Akt/PKB changed dramati-
cally, and it colocalized with NS5B in the perinuclear region (Fig.
6A). The subcellular Akt/PKB distribution depended on the ex-
pression of HCV NS5B (compare solid and dashed arrows), and
the perinuclear location was observed in 95% of the analyzed cells
(n	 150) (Fig. 6B). The same perinuclear colocation of Akt/PKB
and HCV NS5B occurred in Huh7.5 cells stably expressing HCV
nonstructural proteins from the pI389/NS3-3=/LucUbiNeo-ET
subgenomic replicon (Fig. 7), with perinuclear colocalization in
87% of the analyzed cells (n	 150) (Fig. 7B).
To exclude that perinuclear colocalization could be a mere
side effect of overexpression of the relevant proteins, immuno-
cytochemistry was performed with Huh7.5 cells either unin-
fected or infected with HCVp0 (Fig. 8). Uninfected cells
showed Akt/PKB homogeneously distributed in the cytoplasm
and the absence of NS5B, as expected (Fig. 8A, Akt-C and
NS5B-C panels). However, in HCVp0-infected cells Akt/PKB
and HCV NS5B colocalized in the perinuclear region (Fig. 8A).
Akt/PKB relocalization from the cytoplasm to the perinuclear
region was related to expression of NS5B (Fig. 8A, compare
solid and dashed arrows). The perinuclear colocalization was
observed in 82% of the analyzed cells (n 	 150) (Fig. 8B).
Therefore, the NS5B-Akt/PKB interaction resulted in the sub-
cellular relocalization of Akt/PKB from cytoplasmic to perinu-
clear regions, independently of the system used for the intra-
cellular expression of these proteins.
DISCUSSION
The results reported here show interaction between the cellular
kinase Akt/PKB and NS5B, resulting in colocalization of the
FIG 6 Intracellular localization of NS5B-FP and Akt/PKB. (A) Huh7.5
cells transiently transfected with plasmids encoding Akt/PKB (pcFEL)
and/or NS5B-FP (pcDNA-Dest40-NS5B-citrine). Immunocytochemistry
was performed using antibodies against HA (in red), detecting Akt/PKB, or
against GFP (in green), detecting NS5B-FP and with DAPI (in blue), de-
tecting cell nuclei. Upper panels are micrographs showing cells transfected
with a single plasmid encoding either Akt/PKB (left) or NS5B-FP (right).
Nuclear staining in these panels was performed with DAPI. Panels named
Akt/PKB, NS5B, and Merged correspond to transfection experiments with
both Akt/PKB and NS5B-FP. Left panels correspond to a confocal micros-
copy field in which cells transfected with only Akt/PKB (dashed arrow) and
cells transfected with both Akt/PKB and NS5B (solid arrow) are shown.
Panels on the right show only two representative cells, one transiently
cotransfected with both plasmids (solid arrow) and one transiently trans-
fected with only a plasmid encoding Akt/PKB (dashed arrow). Akt panels
correspond to immunostaining with anti-HA, whereas NS5B panels corre-
spond to anti-GFP staining. Merged images (bottom panels) show an over-
lay with colocalization in orange. Scale bars, 10 m. (B) Percentage of cells
in which Akt-NS5B colocalization was observed. Procedures are described
in Materials and Methods.
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two proteins in the perinuclear region of the infected cell. This
places Akt/PKB among other host factors that are relevant for
the HCV infection cycle in terms of their interaction with HCV
NS5B, for example, the cellular proteins human vesicle-associ-
ated membrane-associated protein of 33 kDa (hVAP-33),
PRK2, estrogen receptor, and the retinoblastoma tumor sup-
pressor protein (pRb), among others (32–34). Interventions
targeting virus-host interactions could be relevant for antiviral
drug development.
It has been previously shown that HCV infection inhibits
the PI3K/Akt/mTOR pathway and that inhibition of Akt/PKB
results in a reduction of HCV replication and a large decrease
in the number of HCV-infected cells (13, 14). Our results with
the Akt/PKB inhibitor MK-2206 are consistent with these pre-
vious observations and show a delay of the infection and a
decrease in the amount of progeny virus (Fig. 2C and D). Prob-
ably due to differences in the MOI at which the experiments
were performed (0.5 in this study, 10 in other studies), the
effect was not as pronounced as in previous studies; neverthe-
less, the inhibition pointed at a possible participation of NS5B
in the effect of Akt/PKB. We have also shown that Akt/PKB can
phosphorylate in vitro the HCV NS5B protein. In vitro kinase
assay results obtained with NS5B carrying point mutations at
positions susceptible to be phosphorylated by Akt/PKB have
not been conclusive to map phosphorylation sites. However,
incubation of NS5B with Akt alone or with Akt plus ATP to
carry out NS5B phosphorylation resulted in a pronounced de-
crease of RNA polymerase activity (Fig. 3). Attenuation of RNA
synthesis was strongest when phosphorylation took place, but
to a lesser extent, it also occurred in the presence of solely Akt
(Fig. 3). This result is consistent with the increase in the
amount of intracellular HCV RNA detected in cells treated
with an Akt inhibitor at a short time after infection (7 h p.i.)
(Fig. 2). RNA synthesis defects in HCV NS5B mutants that
mimic phosphorylation at Ser residues have been previously
reported (35). In any case, further experiments with proteins
carrying different combinations of mutated residues as well as
with deletion mutants should be performed to precisely map
the residues that are phosphorylated by Akt/PKB and its sub-
sequent effects on polymerase activity and subcellular localiza-
tion.
Changes in subcellular protein localization are relevant for reg-
ulatory processes. Actually, Akt/PKB can form complexes with
other proteins that do not have to be substrates for its kinase
activity but rather can act as modulators of Akt/PKB biological
activity and function (36, 37). Our results show for the first time
that HCV NS5B interacts with Akt/PKB (Fig. 4; see also Fig. S2 in
the supplemental material). Moreover, Akt/PKB is relocated to
the perinuclear region of infected cells, where it colocalizes with
FIG 7 Subcellular localization of Akt/PKB and NS5B expressed from an HCV
replicon. (A) Immunocytochemistry of Huh7.5 cells carrying HCV sub-
genomic replicon pI389/NS3-3=/LucUbiNeo-ET using antibodies against en-
dogenous Akt/PKB (in red, upper panels), against HCV NS5B (in green, mid-
dle panels), and with DAPI (in blue), detecting cell nuclei. The overlay shows
colocalization in orange. Left panels correspond to a confocal microscopy
field, whereas the panels on the right show only two representative cells. Scale
bars,10 m. (B) Percentage of cells where Akt-NS5B colocalization was ob-
served. Procedures are described in Materials and Methods. FIG 8 Intracellular localization of Akt/PKB and NS5B expressed from
HCVp0. (A) Immunocytochemistry of Huh7.5 cells infected with HCVp0
and visualized with antibodies against Akt/PKB (in red) or NS5B (green)
and with DAPI. Top panels are uninfected control cells visualized with
anti-Akt (left) and anti-NS5B (right) antibodies. Akt/PKB, NS5B, and
merged panels correspond to HCVp0-infected cells. In the merged images
(bottom panel), colocalization is shown in orange. Left panels correspond
to a confocal microscopy field, whereas right panels show a magnification
with representative cells. Solid-line arrows show cells where Akt/PKB co-
localizes with NS5B, whereas dashed-line arrows point at uninfected cells.
The images show a field representative of at least three independent exper-
iments. Scale bars, 10 m. (B) Percentage of cells in which Akt-NS5B
colocalization was observed. Methodological details are described in Ma-
terials and Methods.
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NS5B (Fig. 6 to 8), suggesting a possible function of Akt/PKB in
the replication complex (15, 38–40). HCV NS5A is a component
of the HCV replication complexes and is phosphorylated and hy-
perphosphorylated by cellular kinases, including Akt/PKB (12)
and casein kinase I (41). Analogous to our observations, there is
evidence that simian virus 40 (SV40) T antigen may contribute to
a change in the subcellular localization of Akt/PKB from the nu-
cleus to the cytoplasm, as judged from a comparison of the intra-
cellular location of Akt/PKB in transformed and nontransformed
HEK-293 cells (42).
Akt/PKB activation in Huh7.5 cells occurs at the cytosolic
face of the plasma membrane where activators (PI3P) and ki-
nases (PDK1 and mTORC2) are located (Fig. 9A). Transient,
E2 glycoprotein-mediated Akt/PKB activation has been previ-
ously related to HCV entry into the cell (13). Related to viral
entry, some authors have described a superinfection exclusion
mechanism by which cells currently infected with HCV are
resistant to a secondary infection with the same or a closely
related virus (43–45). These authors suggest that the first virus
prevents secondary infections because it sequesters a limiting
host factor (44, 45). Our results suggest that HCV NS5B might
be the HCV protein that mediates Akt/PKB relocalization to
fulfill a function in the replication complexes. Relocalization of
Akt/PKB by HCV NS5B might also prevent further Akt/PKB
activation in the plasma membrane governed by the E2 glyco-
protein from new virions. In any case, further experiments are
needed to resolve the possible role played by Akt/PKB and HCV
NS5B in the superinfection exclusion process seen for HCV as
well as to map the NS5B and Akt/PKB contact surface.
Based on our results, we propose a model (Fig. 9B) in which
the E2 glycoprotein activates Akt/PKB, allowing HCV entry
(13, 14) and, following virus uncoating and translation, viral
polymerase NS5B sequesters and relocates Akt/PKB to the pe-
rinuclear region, where it can interact with other HCV proteins
(12). Furthermore, this interaction could deplete Akt/PKB
from the plasma membrane, consequently diminishing its sub-
sequent activation and preventing superinfection. Identifica-
tion of the cellular and viral components (both protein and
RNA) that form part of the perinuclear region where Akt/PKB
and NS5B colocalize is currently in progress in our laboratory.
Although many aspects of this model require experimental ver-
ification, the current picture is that cellular pathways involved
in cell cycle, apoptosis, autophagy, and metabolism must be
finely regulated by viral components to the virus’s benefit. In-
teraction with and, most importantly, relocalization of cellular
Akt/PKB could be the way for HCV to control the PI3K/Akt/
FIG 9 (A) Model of Akt activation. Upon interaction of some cellular receptors with specific ligands, the phosphatidylinositol 4,5 bisphosphate 3 kinase (PI3K)
synthesizes phosphatidylinositol 3-phosphate (PIP3), which in turn binds Akt/PKB to relocate it to the plasma membrane. At this location, Akt/PKB is
phosphorylated by phosphoinositide-dependent kinase 1 (PDK1) and the mammalian target of rapamycin complex 2 (mTORC2) to become activated. Activated
Akt/PKB can activate or deactivate its myriad substrates with effects on protein synthesis, cell survival and proliferation, and glucose metabolism among others
(4). (B) Effects of HCV infection on Akt/PKB. Upon interaction of the HCV E2 surface glycoprotein with specific receptors (including CD81 and Claudin-1),
Akt/PKB is activated, promoting HCV entry into the cell. Once HCV uncoats and translates its positive RNA genome, viral proteins are produced, including the
viral polymerase (NS5B). HCV NS5B interacts with Akt/PKB, inducing its subcellular relocalization to the perinuclear region (this study), where interactions
with other HCV proteins (such as NS5A) can occur. This relocalization might affect entry of new HCV particles into the cell (superinfection exclusion) as well
as Akt/PKB signaling.
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mTOR pathway during the HCV life cycle (Fig. 8B). A deeper
knowledge of the NS5B-Akt/PKB molecular interaction could
be used to design small-molecule inhibitors directed to inter-
fere with this critical connection, by analogy to the proposed
new Bcl-2 inhibitors for cancer treatment (46). Furthermore,
Akt/PKB inhibitors currently undergoing clinical trials could
be useful for HCV infection treatment, as it has been recently
showed for those inhibiting mTORC1 (17). Taken together,
these results highlight the importance of the PI3K/Akt/mTOR
pathway in HCV infection.
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